Celldex says barzolvolimab hit all primary and secondary goals in two Phase 3 CSU trialsSep 22Clinical readoutbarzolvolimabCelldex Therapeutics
Cue Biopharma's 8-K confirms Phase 2 CUE-221 data in chronic hives, outlines next stepsSep 21Clinical readoutCue Biopharma, Inc.
Novartis registers Phase 3 urticaria, pruritus trials; posts malaria and leishmaniasis dataSep 11Weekly roundup, 5 itemscipargaminINE963
Sign inSign in